(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Palghar: The Union health ministry has stopped operations and production of Aveo Pharmaceuticals Ltd. (Aveo) following ...

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

The Federal Drug Administration last month approved Journavx, a new kind of non-addictive pain medication. Doctors say ...

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

On January 30, 2025, the US FDA approved Journavx (suzetrigine) 50mg oral tablets to use in the treatment of moderate to severe acute pain, making it the first non-opioid analgesic of its class to ...